Formulation Development of Mirtazapine Liquisolid Compacts: Optimization Using Central Composite Design

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems

Background:

• Mirtazapine, a tetracyclic antidepressant, exhibits poor water solubility, limiting its therapeutic efficacy.
• Improving the dissolution rate of poorly soluble drugs is crucial for enhancing bioavailability.

Purpose of the Study:

• To enhance the dissolution rate of mirtazapine by formulating it as a liquisolid compact.
• To optimize the liquisolid system by investigating the impact of excipient ratio and drug concentration.

Main Methods:

• Liquisolid compacts were prepared using propylene glycol, microcrystalline cellulose, and silicon dioxide.
• Central composite design (CCD) was employed for optimization.
• X-ray powder diffraction (XRD) and Fourier-transform infrared spectroscopy (FTIR) were used for characterization.

Main Results:

• The liquisolid formulation resulted in loss of mirtazapine crystallinity and complete solubilization.
• Drug dissolution was significantly higher in liquisolid compacts compared to conventional tablets.
• The formulation demonstrated uniform drug dispersion within the powder system.

Conclusions:

• The liquisolid technique is a promising approach for improving the dissolution of poorly water-soluble drugs like mirtazapine.
• This method offers a viable strategy for developing more effective oral dosage forms for poorly soluble active pharmaceutical ingredients.